Zurich Cantonal Bank
KYMR icon

Zurich Cantonal Bank’s Kymera Therapeutics KYMR Stock Holding History

Zurich Cantonal Bank’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,631
Closed -$1.22M – 3064
2025
Q4 		$1.22M Buy
+15,631
New +$1.06M ﹤0.01% 1233

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Zurich Cantonal Bank's KYMR Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in Kymera Therapeutics (KYMR) in Q1 2026: 32,061 shares worth $2.67M. The stake represents 0.01% of the portfolio and ranks #887 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in KYMR as recently as Q3 2025.

Zurich Cantonal Bank first reported a position in KYMR in Q3 2021 and has held it in 18 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Zurich Cantonal Bank held 32,061 shares of Kymera Therapeutics worth $2.67M as of Q1 2026.
  • Kymera Therapeutics was a new Zurich Cantonal Bank position in Q1 2026.
  • Kymera Therapeutics made up 0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #887 holding.
  • Zurich Cantonal Bank first reported a position in Kymera Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.